{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:38:23Z","timestamp":1792154303854,"version":"4.4.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11033-023-08666-0","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T23:10:47Z","timestamp":1690153847000},"page":"7815-7823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["Biomarkers of liver diseases"],"prefix":"10.1007","volume":"50","author":[{"given":"Sukhbir Singh","family":"Tamber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rai Barinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-7976","authenticated-orcid":false,"given":"Ramica","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"issue":"8","key":"8666_CR1","first-page":"13","volume":"4","author":"JC Ozougwu","year":"2017","unstructured":"Ozougwu JC (2017) Physiology of the liver. Int J Res Pharm Biosci 4(8):13\u201324","journal-title":"Int J Res Pharm Biosci"},{"key":"8666_CR2","doi-asserted-by":"crossref","unstructured":"Ozougwa JC, Eyo JE (2014) Hepatoprotective effects of Allium cepa (onion) extracts against paracetamol-induced liver damage in rats. Afr J Biotechnol 13(26): 2679\u20132688","DOI":"10.5897\/AJB2014.13815"},{"key":"8666_CR3","unstructured":"Moore KL, Dalley AF, Agur AM (2013) Clinically oriented anatomy. Lippincott Williams & Wilkins"},{"key":"8666_CR4","volume-title":"Textbook of medical physiology","author":"AC Guyton","year":"1986","unstructured":"Guyton AC, Hall JE (1986) Textbook of medical physiology. Saunders, Philadelphia"},{"key":"8666_CR5","doi-asserted-by":"crossref","unstructured":"Yang X, Schnackenberg LK, Shi Q, Salminen WF (2014) Hepatic toxicity biomarkers. In: Biomarkers in toxicology, pp 241\u2013259. Academic Press","DOI":"10.1016\/B978-0-12-404630-6.00013-0"},{"key":"8666_CR6","volume-title":"Casarett and Doull\u2019s toxicology: the basic science of poisons","author":"C Klaassen","year":"2007","unstructured":"Klaassen C (2007) Casarett and Doull\u2019s toxicology: the basic science of poisons. McGraw Hill Professional, New York"},{"issue":"2","key":"8666_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5530\/ijper.54.2.28","volume":"54","author":"AK Shakya","year":"2020","unstructured":"Shakya AK (2020) Drug-induced hepatotoxicity and hepatoprotective medicinal plants: a review. Indian J Pharm Educ Res 54(2):234\u2013250","journal-title":"Indian J Pharm Educ Res"},{"issue":"9","key":"8666_CR8","first-page":"34","volume":"7","author":"M Maqbool","year":"2019","unstructured":"Maqbool M, Rasool S, Dar MA, Bashir R, Khan M (2019) Hepatotoxicity and hepatoprotective agents: a mini review. PharmaTutor 7(9):34\u201340","journal-title":"PharmaTutor"},{"key":"8666_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/B0-12-386860-2\/00367-1","volume":"2","author":"MJ Czaja","year":"2004","unstructured":"Czaja MJ (2004) Forms, of hepatotoxin-induced liver injury. Encycl Gastroenterol 2:365","journal-title":"Encycl Gastroenterol"},{"key":"8666_CR10","unstructured":"Gulati K, Reshi MR, Rai N, Ray A (2018) Hepatotoxicity: its mechanisms, experimental evaluation and protective strategies. Am J Pharmacol 1(1): 1004"},{"issue":"3","key":"8666_CR11","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch T, Neff AP (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76(3):391\u2013396","journal-title":"Am Fam Physician"},{"issue":"1","key":"8666_CR12","first-page":"1385","volume":"8","author":"S Sivakrishnan","year":"2019","unstructured":"Sivakrishnan S (2019) Liver disease overview. World J Pharm Pharmaceut Sci 8(1):1385\u20131395","journal-title":"World J Pharm Pharmaceut Sci"},{"key":"8666_CR13","doi-asserted-by":"crossref","unstructured":"Paniagua AC, Amariles P (2017) Hepatotoxicity by drugs. In: Pharmacokinetics and adverse effects of drugs-mechanisms and risks factors. InTech","DOI":"10.5772\/intechopen.72005"},{"issue":"6","key":"8666_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.2008.058248","volume":"62","author":"R Ramachandran","year":"2009","unstructured":"Ramachandran R, Kakar S (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62(6):481\u2013492","journal-title":"J Clin Pathol"},{"issue":"2","key":"8666_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.26709","volume":"59","author":"DE Kleiner","year":"2014","unstructured":"Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA (2014) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59(2):661\u2013670","journal-title":"Hepatology"},{"issue":"4","key":"8666_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cld.2013.07.004","volume":"17","author":"X Zhang","year":"2013","unstructured":"Zhang X, Ouyang J, Thung SN (2013) Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis 17(4):547\u2013564","journal-title":"Clin Liver Dis"},{"key":"8666_CR17","doi-asserted-by":"crossref","unstructured":"Hayashi PH, Fontana RJ (2014) Clinical features, diagnosis, and natural history of drug-induced liver injury. In: Seminars in liver disease, vol 34, no 02, pp 134\u2013144. Thieme Medical Publishers","DOI":"10.1055\/s-0034-1375955"},{"key":"8666_CR18","first-page":"43","volume":"2","author":"X Yang","year":"2012","unstructured":"Yang X, Salminen WF, Schnackenberg LK (2012) Current and emerging biomarkers of hepatotoxicity. Curr Biomarker Find 2:43","journal-title":"Curr Biomarker Find"},{"issue":"10","key":"8666_CR19","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3389\/fphar.2019.01667","volume":"30","author":"S Fu","year":"2020","unstructured":"Fu S, Wu D, Jiang W, Li J, Long J, Jia C, Zhou T (2020) Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol 30(10):1667","journal-title":"Front Pharmacol"},{"issue":"3","key":"8666_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1503\/cmaj.1040752","volume":"172","author":"EG Giannini","year":"2005","unstructured":"Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. CMAJ 172(3):367\u2013379","journal-title":"CMAJ"},{"issue":"4","key":"8666_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/hep.24229","volume":"53","author":"MS Padda","year":"2011","unstructured":"Padda MS, Sanchez M, Akhtar AJ, Boyer JL (2011) Drug-induced cholestasis. Hepatology 53(4):1377\u20131387","journal-title":"Hepatology"},{"issue":"10","key":"8666_CR22","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3389\/fphar.2019.01482","volume":"11","author":"L Meunier","year":"2019","unstructured":"Meunier L, Larrey D (2019) Drug-induced liver injury: biomarkers, requirements, candidates, and validation. Front Pharmacol 11(10):1482","journal-title":"Front Pharmacol"},{"key":"8666_CR23","doi-asserted-by":"crossref","unstructured":"Anad\u00f3n A, Castellano V, Mart\u00ednez-Larra\u00f1aga MR (2014) Biomarkers of drug toxicity. In: Biomarkers in toxicology, pp 593\u2013607. Academic Press","DOI":"10.1016\/B978-0-12-404630-6.00034-8"},{"issue":"5","key":"8666_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/JLB.3MR0121-277R","volume":"110","author":"YA Ni","year":"2021","unstructured":"Ni YA, Chen H, Nie H, Zheng B, Gong Q (2021) HMGB1: an overview of its roles in the pathogenesis of liver disease. J Leukoc Biol 110(5):987\u2013998","journal-title":"J Leukoc Biol"},{"issue":"1","key":"8666_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2119\/molmed.2013.00099","volume":"19","author":"R Chen","year":"2013","unstructured":"Chen R, Hou W, Zhang Q, Kang R, Fan XG, Tang D (2013) Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med 19(1):357\u2013366","journal-title":"Mol Med"},{"issue":"21","key":"8666_CR26","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.3390\/ijms20215314","volume":"20","author":"B Khambu","year":"2019","unstructured":"Khambu B, Yan S, Huda N, Yin XM (2019) Role of high-mobility group box-1 in liver pathogenesis. Int J Mol Sci 20(21):5314","journal-title":"Int J Mol Sci"},{"issue":"11","key":"8666_CR27","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/liv.13441","volume":"37","author":"RJ Church","year":"2017","unstructured":"Church RJ, Watkins PB (2017) The transformation in biomarker detection and management of drug-induced liver injury. Liver Int 37(11):1582\u20131590","journal-title":"Liver Int"},{"issue":"5","key":"8666_CR28","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/hep.24552","volume":"54","author":"L Li","year":"2011","unstructured":"Li L, Chen L, Hu L, Liu Y, Sun HY, Tang J, Hou YJ, Chang YX, Tu QQ, Feng GS, Shen F (2011) Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 54(5):1620\u20131630","journal-title":"Hepatology"},{"key":"8666_CR29","doi-asserted-by":"crossref","unstructured":"Yates KP, Deppe R, Comerford M, Masuoka H, Cummings OW, Tonascia J, Chalasani N, Vuppalanchi R, NASH CRN (2017) Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. PloS ONE 12(11): e0185813","DOI":"10.1371\/journal.pone.0185813"},{"issue":"5","key":"8666_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1665-2681(19)31247-5","volume":"13","author":"Z Wenfeng","year":"2015","unstructured":"Wenfeng Z, Wu Y, Di M, Gong J, Chuanxin W, Chun H (2015) Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Ann Hepatol 13(5):489\u2013495","journal-title":"Ann Hepatol"},{"key":"8666_CR31","doi-asserted-by":"crossref","unstructured":"Ge X, Arriazu E, Magdaleno F, Antoine DJ, dela Cruz R, Theise N, Nieto N (2018) High mobility group box\u20101 drives fibrosis progression signaling via the receptor for advanced glycation end products in mice. Hepatology 68(6): 2380\u20132404","DOI":"10.1002\/hep.30093"},{"issue":"5","key":"8666_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064373","volume":"8","author":"FP Wang","year":"2013","unstructured":"Wang FP, Li L, Li J, Wang JY, Wang LY, Jiang W (2013) High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K\/Akt and JNK. PLoS ONE 8(5):e64373","journal-title":"PLoS ONE"},{"key":"8666_CR33","doi-asserted-by":"crossref","unstructured":"Kao YH, Jawan B, Goto S, Hung CT, Lin YC, Nakano T, Hsu LW, Lai CY, Tai MH, Chen CL (2008) High-mobility group box 1 protein activates hepatic stellate cells in vitro. In: Transplantation proceedings, vol 40, no 8, pp 2704\u20132705. Elsevier","DOI":"10.1016\/j.transproceed.2008.07.055"},{"issue":"5\u20136","key":"8666_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lfs.2012.07.009","volume":"91","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Lin C, Peng L, Ouyang Y, Cao Y, Wang J, Friedman SL, Guo J (2012) High mobility group box 1 activates toll like receptor 4 signaling in hepatic stellate cells. Life Sci 91(5\u20136):207\u2013212","journal-title":"Life Sci"},{"issue":"6","key":"8666_CR35","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/hep.25572","volume":"55","author":"W Yan","year":"2012","unstructured":"Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A (2012) High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 55(6):1863\u20131875","journal-title":"Hepatology"},{"issue":"1","key":"8666_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0451-6","volume":"6","author":"L Ye","year":"2018","unstructured":"Ye L, Zhang Q, Cheng Y, Chen X, Wang G, Shi M, Zhang T, Cao Y, Pan H, Zhang L, Wang G (2018) Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion. J Immunother Cancer 6(1):1\u20135","journal-title":"J Immunother Cancer"},{"issue":"9","key":"8666_CR37","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/liv.13424","volume":"37","author":"G Lv","year":"2017","unstructured":"Lv G, Wu M, Wang M, Jiang X, Du J, Zhang K, Li D, Ma N, Peng Y, Wang L, Zhou L (2017) miR-320a regulates high mobility group box 1 expression and inhibits invasion and metastasis in hepatocellular carcinoma. Liver Int 37(9):1354\u20131364","journal-title":"Liver Int"},{"issue":"1","key":"8666_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-015-0323-z","volume":"10","author":"H Li","year":"2015","unstructured":"Li H, Huang W, Luo R (2015) Retracted article: the microrna-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1. Diagn Pathol 10(1):1\u20131","journal-title":"Diagn Pathol"},{"issue":"2","key":"8666_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/jir.2010.0019","volume":"31","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Yao YM, Huang LF, Dong N, Yu Y, Sheng ZY (2011) The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res 31(2):249\u2013257","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"8666_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.5551\/jat.31088","volume":"23","author":"JW Ding","year":"2016","unstructured":"Ding JW, Zheng XX, Zhou T, Tong XH, Luo CY, Wang XA (2016) HMGB1 modulates the Treg\/Th17 ratio in atherosclerotic patients. J Atheroscler Thromb 23(6):737\u2013745","journal-title":"J Atheroscler Thromb"},{"key":"8666_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/295081","volume":"2012","author":"Y Shi","year":"2012","unstructured":"Shi Y, Sandoghchian Shotorbani S, Su Z et al (2012) Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012:295081","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"8666_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1189\/jlb.0306173","volume":"81","author":"G Sitia","year":"2007","unstructured":"Sitia G, Iannacone M, M\u00fcller S, Bianchi ME, Guidotti LG (2007) Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 81(1):100\u2013107","journal-title":"J Leukoc Biol"},{"issue":"7","key":"8666_CR43","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20042614","volume":"201","author":"A Tsung","year":"2005","unstructured":"Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201(7):1135\u20131143","journal-title":"J Exp Med"},{"issue":"1","key":"8666_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/hep.26346","volume":"58","author":"GW Nace","year":"2013","unstructured":"Nace GW, Huang H, Klune JR, Eid RE, Rosborough BR, Korff S, Li S, Shapiro RA, Stolz DB, Sodhi CP, Hackam DJ (2013) Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology 58(1):374\u2013387","journal-title":"Hepatology"},{"key":"8666_CR45","doi-asserted-by":"crossref","unstructured":"Cai C, Shi X, Korff S, Zhang J, Loughran PA, Ruan X, Zhang Y, Liu L, Billiar TR (2013) CD14 contributes to warm hepatic ischemia-reperfusion injury in mice. Shock (Augusta, Ga.) 40(2): 115","DOI":"10.1097\/SHK.0b013e318299d1a7"},{"key":"8666_CR46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI76887","volume":"125","author":"P Huebener","year":"2015","unstructured":"Huebener P, Pradere JP, Hernandez C et al (2015) The HMGB1\/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest 125:539\u2013550","journal-title":"J Clin Invest"},{"issue":"6","key":"8666_CR47","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1083\/jcb.138.6.1379","volume":"138","author":"C Caulin","year":"1997","unstructured":"Caulin C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138(6):1379\u20131394 ([PubMed: 9298992])","journal-title":"J Cell Biol"},{"key":"8666_CR48","doi-asserted-by":"crossref","unstructured":"Mannery YO, McClain CJ, Vos MB (2011) Keratin 18, apoptosis, and liver disease in children. Curr Pediatr Rev 7(4): 310\u2013315","DOI":"10.2174\/157339611796892364"},{"issue":"5","key":"8666_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J","volume":"187","author":"MP Leers","year":"1999","unstructured":"Leers MP, K\u00f6lgen W, Bj\u00f6rklund V, Bergman T, Tribbick G, Persson B, Bj\u00f6rklund P, Ramaekers FC, Bj\u00f6rklund B, Nap M, J\u00f6rnvall H (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187(5):567\u2013572","journal-title":"J Pathol"},{"issue":"10","key":"8666_CR50","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1593\/neo.08620","volume":"10","author":"EC de Haas","year":"2008","unstructured":"de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA (2008) Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10(10):1041\u20131048","journal-title":"Neoplasia"},{"key":"8666_CR51","doi-asserted-by":"crossref","unstructured":"Tarrant J (2017) Emerging translatable safety biomarkers. Comprehensive medicinal chemistry III, pp 255\u2013284. Elsevier, Oxford","DOI":"10.1016\/B978-0-12-409547-2.12387-X"},{"issue":"3","key":"8666_CR52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1139\/O09-008","volume":"87","author":"V Mastorodemos","year":"2009","unstructured":"Mastorodemos V, Kotzamani D, Zaganas I, Arianoglou G, Latsoudis H, Plaitakis A (2009) Human GLUD1 and GLUD2 glutamate dehydrogenase localize to mitochondria and endoplasmic reticulum. Biochem Cell Biol 87(3):505\u2013516","journal-title":"Biochem Cell Biol"},{"key":"8666_CR53","doi-asserted-by":"crossref","unstructured":"O'brien PJ, Slaughter MR, Polley SR, Kramer K (2002) Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim 36(3): 313\u2013321","DOI":"10.1258\/002367702320162414"},{"issue":"4","key":"8666_CR54","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1172\/JCI59755","volume":"122","author":"MR McGill","year":"2012","unstructured":"McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H (2012) The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Investig 122(4):1574\u20131583","journal-title":"J Clin Investig"},{"issue":"3","key":"8666_CR55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/01926230252929945","volume":"30","author":"PS Giffen","year":"2002","unstructured":"Giffen PS, Pick CR, Price MA, Williams A, York MJ (2002) Alpha-glutathione S-transferase in the assessment of hepatotoxicity\u2014its diagnostic utility in comparison with other recognized markers in the Wistar Han rat. Toxicol Pathol 30(3):365\u2013372","journal-title":"Toxicol Pathol"},{"issue":"3","key":"8666_CR56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tox.2007.11.021","volume":"245","author":"J Ozer","year":"2008","unstructured":"Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245(3):194\u2013205","journal-title":"Toxicology"},{"key":"8666_CR57","doi-asserted-by":"crossref","unstructured":"Smith GS, Walter GL, Walker RM (2013) Clinical pathology in non-clinical toxicology testing. In: Haschek and Rousseaux\u2019s handbook of toxicologic pathology, pp 565\u2013594. Academic Press","DOI":"10.1016\/B978-0-12-415759-0.00018-2"},{"key":"8666_CR58","doi-asserted-by":"crossref","unstructured":"Zelewski M, Swierczy\u0144ski J (1991) Malic enzyme in human liver. Intracellular distribution, purification and properties of cytosolic isozyme. Eur J Biochem 201(2): 339\u2013345","DOI":"10.1111\/j.1432-1033.1991.tb16291.x"},{"issue":"5","key":"8666_CR59","first-page":"619","volume":"105","author":"L Zieve","year":"1985","unstructured":"Zieve L, Anderson WR, Dozeman R, Draves K, Lyftogt C (1985) Acetaminophen liver injury: sequential changes in two biochemical indices of regeneration and their relationship to histologic alterations. J Lab Clin Med 105(5):619\u2013624","journal-title":"J Lab Clin Med"},{"issue":"4","key":"8666_CR60","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0009-9120(90)80064-P","volume":"23","author":"M Kawai","year":"1990","unstructured":"Kawai M, Hosaki S (1990) Clinical usefulness of malate dehydrogenase and its mitochondrial isoenzyme in comparison with aspartate aminotransferase and its mitochondrial isoenzyme in sera of patients with liver disease. Clin Biochem 23(4):327\u2013334","journal-title":"Clin Biochem"},{"issue":"2","key":"8666_CR61","first-page":"31","volume":"45","author":"MK Misra","year":"1991","unstructured":"Misra MK, Khanna AK, Sharma R, Srinivasan S (1991) Serum malate dehydrogenase (MDH) in portal hypertension\u2014its value as a diagnostic and prognostic indicator. Indian J Med Sci 45(2):31\u201334","journal-title":"Indian J Med Sci"},{"issue":"2","key":"8666_CR62","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.taap.2009.12.015","volume":"243","author":"E Marrer","year":"2010","unstructured":"Marrer E, Dieterle F (2010) Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol 243(2):167\u2013179","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"8666_CR63","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archsurg.135.2.198","volume":"135","author":"DJ Koo","year":"2000","unstructured":"Koo DJ, Zhou M, Chaudry IH, Wang P (2000) Plasma \u03b1-glutathione S-transferase: a sensitive indicator of hepatocellular damage during polymicrobial sepsis. Arch Surg 135(2):198\u2013203","journal-title":"Arch Surg"},{"key":"8666_CR64","doi-asserted-by":"crossref","unstructured":"Loguercio C, Tuccillo C, Caporaso N, Blanco GD, Morisco F, Guerriero C, Di Santolo SS, Valenza LM, Blanco CD (1998) Determination of plasma alpha\u2010glutathione S\u2010transferases in patients with HCV\u2010related chronic infection: its significance and possible clinical relevance. Liver 18(3): 166\u2013172","DOI":"10.1111\/j.1600-0676.1998.tb00145.x"},{"issue":"60","key":"8666_CR65","first-page":"1747","volume":"51","author":"T Suehiro","year":"2004","unstructured":"Suehiro T, Matsumata T, Shikada Y, Shimada M, Shirabe K, Sugimachi K (2004) Change in alpha glutathione s-transferase levels during liver resection. Hepatogastroenterology 51(60):1747\u20131750","journal-title":"Hepatogastroenterology"},{"key":"8666_CR66","first-page":"2019","volume":"20","author":"J Czuczejko","year":"2019","unstructured":"Czuczejko J, Mila-Kierzenkowska C, Szewczyk-Golec K (2019) Plasma \u03b1-glutathione S-transferase evaluation in patients with acute and chronic liver injury. Can J Gastroenterol Hepatol 20:2019","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"10","key":"8666_CR67","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1034\/j.1399-6576.2001.451009.x","volume":"45","author":"H Higuchi","year":"2001","unstructured":"Higuchi H, Adachi Y, Wada H, Kanno M, Satoh T (2001) Comparison of plasma \u03b1 glutathione S-transferase concentrations during and after low-flow sevoflurane or isoflurane anaesthesia. Acta Anaesthesiol Scand 45(10):1226\u20131229","journal-title":"Acta Anaesthesiol Scand"},{"key":"8666_CR68","doi-asserted-by":"crossref","unstructured":"Rodrigo L, Hern\u00e1ndez AF, Lopez-Caballero JJ, Gil F, Pla A (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chemico-Biol Interact 137(2): 123\u2013137","DOI":"10.1016\/S0009-2797(01)00225-3"},{"issue":"2","key":"8666_CR69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/clinchem\/48.2.261","volume":"48","author":"N Ferr\u00e9","year":"2002","unstructured":"Ferr\u00e9 N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J (2002) Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 48(2):261\u2013268","journal-title":"Clin Chem"},{"issue":"2","key":"8666_CR70","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0021-9150(98)00084-7","volume":"139","author":"KR Feingold","year":"1998","unstructured":"Feingold KR, Memon RA, Moser AH, Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139(2):307\u2013315","journal-title":"Atherosclerosis"},{"issue":"5","key":"8666_CR71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1021\/tx034203n","volume":"17","author":"G Meneses-Lorente","year":"2004","unstructured":"Meneses-Lorente G, Guest PC, Lawrence J, Muniappa N, Knowles MR, Skynner HA, Salim K, Cristea I, Mortishire-Smith R, Gaskell SJ, Watt A (2004) A proteomic investigation of drug-induced steatosis in rat liver. Chem Res Toxicol 17(5):605\u2013612","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"8666_CR72","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1517\/14622416.3.3.341","volume":"3","author":"CE Furlong","year":"2002","unstructured":"Furlong CE, Cole TB, Jarvik GP, Costa LG (2002) Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3(3):341\u2013348","journal-title":"Pharmacogenomics"},{"key":"8666_CR73","doi-asserted-by":"crossref","unstructured":"Ha MJ, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15: 509\u2013524","DOI":"10.1038\/nrm3838"},{"issue":"16","key":"8666_CR74","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.1093\/nar\/gkr254","volume":"39","author":"A Turchinovich","year":"2011","unstructured":"Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39(16):7223\u20137233","journal-title":"Nucleic Acids Res"},{"key":"8666_CR75","doi-asserted-by":"crossref","unstructured":"Arrese M, Eguchi A, Feldstein AE (2015) Circulating microRNAs: emerging biomarkers of liver disease. In: Seminars in liver disease, vol 35, no 01, pp 043\u2013054. Thieme Medical Publishers","DOI":"10.1055\/s-0034-1397348"},{"issue":"5","key":"8666_CR76","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","volume":"64","author":"CJ Pirola","year":"2015","unstructured":"Pirola CJ, Gianotti TF, Casta\u00f1o GO, Mallardi P, San Martino J, Ledesma MM, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S (2015) Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64(5):800\u2013812","journal-title":"Gut"},{"issue":"6","key":"8666_CR77","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/jat.2960","volume":"34","author":"JD Clarke","year":"2014","unstructured":"Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ (2014) Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol 34(6):726\u2013732","journal-title":"J Appl Toxicol"},{"issue":"424","key":"8666_CR78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cca.2013.05.021","volume":"23","author":"H Yamada","year":"2013","unstructured":"Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, Hamajima N (2013) Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 23(424):99\u2013103","journal-title":"Clin Chim Acta"},{"issue":"9","key":"8666_CR79","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/apt.12649","volume":"39","author":"RJ Longchamps","year":"2014","unstructured":"Longchamps RJ, Abey SK, Martino AC, Henderson WA (2014) Gender-associated cell-free microRNA profiles in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 39(9):997","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"8666_CR80","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nrgastro.2013.87","volume":"10","author":"G Szabo","year":"2013","unstructured":"Szabo G, Bala S (2013) MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10(9):542\u2013552","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"8666_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016081","volume":"6","author":"Y Murakami","year":"2011","unstructured":"Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T, Shimotohno K (2011) The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE 6(1):e16081","journal-title":"PLoS ONE"},{"issue":"1","key":"8666_CR82","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.23922","volume":"53","author":"C Roderburg","year":"2011","unstructured":"Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53(1):209\u2013218","journal-title":"Hepatology"},{"key":"8666_CR83","doi-asserted-by":"crossref","unstructured":"Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. In: Seminars in oncology, vol 38, no 6, pp 752\u2013763. WB Saunders","DOI":"10.1053\/j.seminoncol.2011.08.001"},{"issue":"5","key":"8666_CR84","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/hep.25873","volume":"56","author":"S Bala","year":"2012","unstructured":"Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G (2012) Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 56(5):1946\u20131957","journal-title":"Hepatology"},{"issue":"11","key":"8666_CR85","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1073\/pnas.0813371106","volume":"106","author":"K Wang","year":"2009","unstructured":"Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci 106(11):4402\u20134407","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"8666_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037395","volume":"7","author":"YW Su","year":"2012","unstructured":"Su YW, Chen X, Jiang ZZ, Wang T, Wang C, Zhang Y, Wen J, Xue M, Zhu D, Zhang Y, Su YJ (2012) A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS ONE 7(5):e37395","journal-title":"PLoS ONE"},{"key":"8666_CR87","doi-asserted-by":"crossref","unstructured":"Starkey Lewis PJ et al (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54: 1767\u20131776","DOI":"10.1002\/hep.24538"},{"issue":"1","key":"8666_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-10-151","volume":"10","author":"S Bala","year":"2012","unstructured":"Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G (2012) Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 10(1):1","journal-title":"J Transl Med"},{"issue":"5","key":"8666_CR89","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/hep.25849","volume":"56","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S (2012) Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 56(5):1631\u20131640","journal-title":"Hepatology"},{"issue":"7","key":"8666_CR90","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1111\/j.1365-2893.2011.01443.x","volume":"18","author":"F Ji","year":"2011","unstructured":"Ji F, Yang B, Peng X, Ding H, You H, Tien P (2011) Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepatitis 18(7):e242\u2013e251","journal-title":"J Viral Hepatitis"},{"issue":"12","key":"8666_CR91","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1373\/clinchem.2010.147850","volume":"56","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56(12):1830\u20131838","journal-title":"Clin Chem"},{"issue":"4","key":"8666_CR92","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0092-8674(79)90103-X","volume":"16","author":"DR Senger","year":"1979","unstructured":"Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16(4):885\u2013893","journal-title":"Cell"},{"issue":"1","key":"8666_CR93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/hepr.12166","volume":"44","author":"S Nagoshi","year":"2014","unstructured":"Nagoshi S (2014) Osteopontin: versatile modulator of liver diseases. Hepatol Res 44(1):22\u201330","journal-title":"Hepatol Res"},{"issue":"2","key":"8666_CR94","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/hep.24701","volume":"55","author":"R Urtasun","year":"2012","unstructured":"Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, Ge X, Fiel MI, Nieto N (2012) Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin \u03b1V\u03b23 engagement and PI3K\/pAkt\/NF\u03baB signaling. Hepatology 55(2):594\u2013608","journal-title":"Hepatology"},{"issue":"3","key":"8666_CR95","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1006\/bbrc.1999.0372","volume":"256","author":"R Kawashima","year":"1999","unstructured":"Kawashima R, Mochida S, Matsui A, YouLuTuZ Y, Ishikawa K, Toshima K, Yamanobe F, Inao M, Ikeda H, Ohno A, Nagoshi S (1999) Expression of osteopontin in Kupffer cells and hepatic macrophages and stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 256(3):527\u2013531","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"8666_CR96","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.aohep.2020.01.001","volume":"19","author":"R Bruha","year":"2020","unstructured":"Bruha R, Vitek L, Smid V (2020) Osteopontin\u2014a potential biomarker of advanced liver disease. Ann Hepatol 19(4):344\u2013352","journal-title":"Ann Hepatol"},{"issue":"25","key":"8666_CR97","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199306243282501","volume":"328","author":"H Tsukuma","year":"1993","unstructured":"Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328(25):1797\u20131801","journal-title":"N Engl J Med"},{"issue":"3","key":"8666_CR98","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jhep.2005.03.019","volume":"43","author":"AM Di Bisceglie","year":"2005","unstructured":"Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM (2005) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial. J Hepatol 43(3):434\u2013441","journal-title":"J Hepatol"},{"issue":"43","key":"8666_CR99","first-page":"235","volume":"49","author":"J Ikoma","year":"2002","unstructured":"Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y (2002) Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 49(43):235\u2013238","journal-title":"Hepatogastroenterology"},{"issue":"11","key":"8666_CR100","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1046\/j.1440-1746.2001.02610.x","volume":"16","author":"H Okuda","year":"2001","unstructured":"Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki K, Nakano M (2001) Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for \u03b1-fetoprotein alone and those seropositive for des-\u03b3-carboxy prothrombin alone 1. J Gastroenterol Hepatol 16(11):1290\u20131296","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"8666_CR101","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/2667-3592.301448","volume":"8","author":"Y Waikar","year":"2019","unstructured":"Waikar Y (2019) Biomarkers of liver injury. Indian J Pediatr 8(2):70","journal-title":"Indian J Pediatr"},{"key":"8666_CR102","unstructured":"Lala V, Zubair M, Minter D (2023) Liver function tests. StatPearls"},{"key":"8666_CR103","unstructured":"Adigun OO, Yarrarapu SN, Zubair M, Khetarpal S (2023) Alpha fetoprotein. StatPearls"},{"issue":"7","key":"8666_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28272","volume":"67","author":"N Nourkami-Tutdibi","year":"2020","unstructured":"Nourkami-Tutdibi N, Graf N, Beier R, Zemlin M, Tutdibi E (2020) Plasma levels of osteopontin from birth to adulthood. Pediatr Blood Cancer 67(7):e28272","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"8666_CR105","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/biom12040544","volume":"12","author":"M \u0160tros","year":"2022","unstructured":"\u0160tros M, Polansk\u00e1 EV, Hlav\u00e1\u010dov\u00e1 T, Skl\u00e1dal P (2022) Progress in assays of HMGB1 levels in human plasma\u2014the potential prognostic value in COVID-19. Biomolecules 12(4):544","journal-title":"Biomolecules"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08666-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08666-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T11:10:42Z","timestamp":1702811442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08666-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":105,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["8666"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08666-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"26 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest between the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}}]}}